Fig. 4From: Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical programChange from baseline in systolic blood pressure at Week 40 by use of antihypertensive medication at baseline. Data taken from the safety population of SURPASS 1–5 pooled. SBP systolic blood pressure, r correlation coefficient, TZP tirzepatideBack to article page